Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Objectives:

The investigators examined whether rosiglitazone, a thiazolidinedione (TZD), is beneficial for pre-diabetes mellitus (DM) adults with documented coronary artery disease (CAD).

Background:

Microvascular and macrovascular complications are common in type 2 DM. There is no evidence about the effects of TZDs, synthetic peroxisome proliferator-activated receptor (PPAR)-γ activators (insulin sensitizers and adipose transcriptional regulation and anti-inflammatory process activators) on pre-DM patients with documented CAD.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cheng-Kung University Hospital
• Treatments: Rosiglitazone

Criteria

Inclusion Criteria:

• documented CAD by angiography

• insulin resistance or glucose intolerance

• 18 to 80 years of age

Exclusion Criteria:

• under DM treatment

• allergy to TZD

• active inflammation

• chronic disease under NSAID treatment

• active heart failure

• unwilling or unable to sign inform consents